First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer

First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer

Background: Platinum-based chemotherapy combined with immune checkpoint inhibitor therapy has recently been introduced for treating extensive-stage small-cell lung cancer (ES-SCLC). In the Phase III CASPIAN study, first-line etoposide (Etoposide) with cisplatin / carboplatin (EP) plus durvalumab sig...

Full description

Saved in:
Bibliographic Details
Main Authors: Eisuke Mochizuki, Shun Matsuura, Naoki Koshimizu, Suguru Kojima, Shogo Sakurai, Satoshi Kishimoto, Mitsuru Niwa, Masayuki Watanuki, Ryunosuke Inaba, Sho Takuma, Yusuke Inoue, Masato Karayama, Naoki Inui, Takafumi Suda
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Cancer Treatment and Research Communications
Subjects:
CASPIAN
Durvalumab
Extensive-stage small-cell lung cancer
Japanese patients
Online Access:http://www.sciencedirect.com/science/article/pii/S246829422500108X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S246829422500108X

Similar Items